相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome
Emily K. Glover et al.
TRANSPLANTATION (2023)
Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study
Esra Baskin et al.
JOURNAL OF NEPHROLOGY (2022)
Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome
Cristina Casas Gonzalez et al.
TRANSPLANTATION PROCEEDINGS (2022)
FC 115: Long-Term Outcomes in Eculizumab-Treated Kidney Transplant Patients Enrolled in the Global Atypical Haemolytic Uraemic Syndrome Registry
Maria Gema Ariceta Iraola et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findingss and outcomes of a case series in adults and children treated with eculizumab
Lilian Monteiro Pereira Palma et al.
CLINICAL KIDNEY JOURNAL (2021)
Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study
Jose Portoles et al.
CLINICAL KIDNEY JOURNAL (2021)
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment
Gema Ariceta et al.
KIDNEY INTERNATIONAL (2021)
Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal
Caroline Duineveld et al.
CLINICAL KIDNEY JOURNAL (2021)
Eculizumab and aHUS: to stop or not
Robert A. Brodsky
BLOOD (2021)
Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored Eculizumab
Gianluigi Ardissino et al.
JOURNAL OF NEPHROLOGY (2021)
Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
Gema Ariceta et al.
CLINICAL KIDNEY JOURNAL (2021)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience
Sam Kant et al.
BMC NEPHROLOGY (2020)
Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review
Kevin Yan et al.
CLINICAL EPIDEMIOLOGY (2020)
Methodological quality of case series studies: an introduction to the JBI critical appraisal tool
Zachary Munn et al.
JBI EVIDENCE SYNTHESIS (2020)
Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis
Maria L. Gonzalez Suarez et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience
Nadir Alpay et al.
TRANSPLANTATION PROCEEDINGS (2019)
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Kioa L. Wijnsma et al.
PEDIATRIC NEPHROLOGY (2019)
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome
Andrew M. Siedlecki et al.
KIDNEY INTERNATIONAL REPORTS (2019)
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens
Vinod Krishnappa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2018)
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Timothy H. J. Goodship et al.
KIDNEY INTERNATIONAL (2017)
Eculizumab in secondary atypical haemolytic uraemic syndrome
Teresa Cavero et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis
Christophe M. Legendre et al.
TRANSPLANT INTERNATIONAL (2017)
Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence
Charlene Levi et al.
TRANSPLANTATION (2017)
Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series
Caroline Duineveld et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature
Sabrina Milan Manani et al.
NEPHRON (2017)
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience
N. S. Sheerin et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2016)
Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort
A. Mallett et al.
INTERNAL MEDICINE JOURNAL (2015)
Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Gwenaelle Sana et al.
PEDIATRIC NEPHROLOGY (2014)
Atypical Hemolytic Uremic Syndrome Recurrence After Kidney Transplantation
Dany Matar et al.
TRANSPLANTATION (2014)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation
J. Zuber et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
aHUS caused by complement dysregulation: new therapies on the horizon
Aoife M. Waters et al.
PEDIATRIC NEPHROLOGY (2011)
Pulse Cyclophosphamide Therapy and Clinical Remission in Atypical Hemolytic Uremic Syndrome With Anti-Complement Factor H Autoantibodies
Olivia Boyer et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom
C. Mark Taylor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype
Marina Noris et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
Gema Ariceta et al.
PEDIATRIC NEPHROLOGY (2009)
Complement and the atypical hemolytic uremic syndrome in children
Chantal Loirat et al.
PEDIATRIC NEPHROLOGY (2008)
Genetics of HUS:: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
Jessica Caprioli et al.
BLOOD (2006)
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance-of genetic background
Elena Bresin et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32
J Esparza-Gordillo et al.
HUMAN MOLECULAR GENETICS (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes
D Barz et al.
THROMBOSIS RESEARCH (2002)
Plasmapheresis in thrombotic microangiopathy-associated syndromes: Review of outcome data derived from clinical trials and open studies
H von Baeyer
THERAPEUTIC APHERESIS (2002)
分享论文
